Resources

BIA welcomed the focus on life sciences SMEs, engineering biology, and the measures designed to help high-growth companies scale and remain rooted in the UK.

The UK’s Minster of State for Science, Research, and Innovation, Lord Patrick Vallance, London & Partners’ CEO, Laura Citron OBE, and Steve Bates OBE, CEO of the UK Bioindustry Association (BIA), are formally launching London Life Sciences Week on the UK stand at the BIO International Convention on Tuesday, 17 June 2025.

BIA has released a new explainer highlighting why the UK is well-positioned to lead in functional genomics, thanks to its unparalleled research capacity and exceptional talent pool.

Steve Bates OBE, CEO of the UK BioIndustry Association, responded to the government's Spending Review.

As the BIA Parliament Day marks its 25th year, 50 senior figures from the UK life sciences community are gathering in Westminster to urge bold government action to deliver much-needed growth for the UK economy.  

The proposals outlined in the report are a major step towards realising BIA’s long-held goal of increasing investment from UK pension funds into UK life sciences.

BIA publishes its 10-year Vision for the UK life science sector, the culmination of 18 months of research and engagement with members and the broader life science ecosystem.

We are calling on the UK government to mandate pension funds to invest in high-growth UK sectors, as new data from its latest report shows British pension schemes are still missing from the biggest biotech deals. 

ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, has revealed the keynote speakers for its flagship event, Drug Discovery 2025

The BioIndustry Association (BIA) has today published a report highlighting the rapid growth of the UK’s Deep Biotech sector.

The UK pavilion at SynBioBeta 2025 will unite leading UK engineering biology companies and ecosystem partners to highlight the UK’s world-class strengths in engineering biology.

Oligos explainer: A new frontier in precision medicine, highlights the transformative potential of oligonucleotide therapies. These precision medicines, which use short DNA or RNA molecules to target specific genes, offer groundbreaking solutions for diseases previously deemed untreatable, from rare genetic disorders to cancer.

Up to 70,000 new jobs will be needed in the UK life sciences sector over the next decade to unlock its potential in growing the UK economy, according to a new report.

New Women in Biotech leadership report is first in comprehensively collecting and examining C-suite gender leadership data for UK biotech. The report identifies clear successes of female leadership at the same time as highlighting sustained challenges.  

The UK biotech sector soared in 2024, raising £3.5 billion—a 94% surge—evidencing its resilience, global appeal, and untapped potential for UK investors amidst calls for pension reform.

BIA today announces Blood Cancer UK as its charity partner of the year for 2025. This partnership demonstrates BIA’s commitment to driving meaningful change through collaboration.

Dr Mahony will work with the UK Government to champion investment into the UK’s innovative life sciences and biotech sector, including playing a key role in the ongoing pension reforms led by Chancellor Rachel Reeves MP.

BIA, MedCity, and London & Partners announce the launch of London Life Sciences Week (LLSW), celebrating the UK’s thriving life sciences ecosystem and bringing together international investors, industry leaders, and cutting-edge innovators.

Read our statement welcoming the Chancellor's recommitment to R&D tax credits, new funding initiatives, and sustained support for biotechnology and medical science.

The UK biotech sector secured an impressive £808 million in Q3 2024, defying tough global market conditions and demonstrating sustained investor confidence. Read our latest report to find out more.